Secretory immunoglobulin A and inhibitory activity of bacterial adherence to epithelial cells in urine from patients with urinary tract infections

Trinchieri, Alberto; Braceschi, L.; Tiranti, D.; Dell'Acqua, S; Mandressi, A.; Pisani, E.

doi:10.1007/bf00300776

Cited by 31 publications

(11 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…UPEC infection elicits Ab responses in animal models and humans. Both IgG and secretory IgA have been found in urine and act as neutralizing Abs (32)(33)(34). A variety of vaccine candidates has been tested in both animal models and humans with the purpose of evoking protective humoral responses (16,17).…”

Section: Discussionmentioning

confidence: 99%

Antigen-Specific Responses Accelerate Bacterial Clearance in the Bladder

Thumbikat¹,

Waltenbaugh

Schaeffer³

et al. 2006

The Journal of Immunology

100

View full text Add to dashboard Cite

Urinary tract infections (UTIs) cause patient morbidity and have a substantial economic impact. Half of all women will suffer a UTI at least once, and 25% of these women will have recurrent infections. That 75% of previously infected women do not become reinfected strongly suggests a role for an adaptive immune response. The goal of this study was to characterize the adaptive immune responses to uropathogenic Escherichia coli (UPEC), the predominant uropathogen. A novel murine model of UTI reinfection was developed using the prototypic cystitis UPEC isolate NU14 harboring a plasmid encoding OVA as a unique antigenic marker. Bacterial colonization of the bladder was quantified following one or more infections with NU14-OVA. Animals developed anti-OVA serum IgG and IgM titers after the initial infection and marked up-regulation of activation markers on splenic T cells. We observed a 95% reduction in bacterial colonization upon reinfection, and splenic leukocytes showed Ag-specific proliferation in vitro. Adoptive transfer of splenic T cells or passive transfer of serum from previously infected mice protected naive syngeneic mice from UPEC colonization. These findings support our hypothesis that adaptive immune responses to UPEC protect the bladder from reinfection and form the basis of understanding susceptibility to recurrent UTI in women.

show abstract

Section: Discussionmentioning

confidence: 99%

Antigen-Specific Responses Accelerate Bacterial Clearance in the Bladder

Thumbikat¹,

Waltenbaugh

Schaeffer³

et al. 2006

The Journal of Immunology

100

View full text Add to dashboard Cite

show abstract

“…UPEC-specific antibodies are detected in the urine of infected patients (202) and in the urine or serum of animals exposed to UPEC antigens (116,217,260,264). Urinary IgG and IgA from UTI patients are capable of inhibiting UPEC adherence (58,249,263). Patient studies have also suggested that antibody responses to pyelonephritis are, in general, stronger and last longer than humoral responses to cystitis (80,134,135).…”

Section: Covert Operations: Cellular and Humoral Adaptive Immune Respmentioning

confidence: 99%

Waging War against UropathogenicEscherichia coli: Winning Back the Urinary Tract

2010

View full text Add to dashboard Cite

Urinary tract infection (UTI) caused by uropathogenic Escherichia coli (UPEC) is a substantial economic and societal burden-a formidable public health issue. Symptomatic UTI causes significant discomfort in infected patients, results in lost productivity, predisposes individuals to more serious infections, and usually necessitates antibiotic therapy. There is no licensed vaccine available for prevention of UTI in humans in the United States, likely due to the challenge of targeting a relatively heterogeneous group of pathogenic strains in a unique physiological niche. Despite significant advances in the understanding of UPEC biology, mechanistic details regarding the host response to UTI and full comprehension of genetic loci that influence susceptibility require additional work. Currently, there is an appreciation for the role of classic innate immune responses-from pattern receptor recognition to recruitment of phagocytic cells-that occur during UPEC-mediated UTI. There is, however, a clear disconnect regarding how factors involved in the innate immune response to UPEC stimulate acquired immunity that facilitates enhanced clearance upon reinfection. Unraveling the molecular details of this process is vital in the development of a successful vaccine for prevention of human UTI. Here, we survey the current understanding of host responses to UPEC-mediated UTI with an eye on molecular and cellular factors whose activity may be harnessed by a vaccine that stimulates lasting and sterilizing immunity. MISSION: ERADICATE UPEC-MEDIATED UTIUrinary tract infection (UTI) is one of the most common infections in humans. Bacteria present in fecal matter inoculate the periurethral area, then the bladder (124, 176, 291), causing symptoms clinically termed cystitis. Left untreated, bacteria ascend the ureters to the kidney and establish a secondary infection, acute pyelonephritis. At this juncture, there is risk of permanent renal scarring, and bacteria can access the bloodstream (282). It is estimated that 40% of women and 12% of men will experience a symptomatic UTI, with incidences peaking in their early 20s or after age 85, respectively (75, 185). Approximately 25% of these women will experience recurrence within 6 to 12 months (75, 185). Uropathogenic Escherichia coli (UPEC) is the most common etiological agent responsible for uncomplicated UTI (93, 94,282). Uropathogenic strains are classified as extraintestinal pathogenic E. coli, a broad grouping of E. coli that cause diseases other than gastroenteritis and typically lack a type III secretion system (171,220,221,283,284). Nonetheless, UPEC strains express an assortment of virulence and fitness factors that aid in successful colonization of the mammalian urinary tract (126,136). In the United States alone, the estimated annual societal cost of UTI is more than 3 billion dollars (159).Despite a relatively in-depth knowledge base for UPEC physiology and virulence mechanisms (reviewed in references 54, 126, 136, and 284), no licensed vaccine to prevent UTI exists in the Un...

show abstract

“…It is increasingly accepted that salivary IgA might play a minor role in saliva-mediated aggregation of bacteria [14]. In histological examinations, Stephens and his colleagues [15] found that immunoglobulin was rarely associated with meningococci on the mucosal surface.…”

Section: Discussionmentioning

confidence: 99%

Inhibitory effect of saliva from secretors and non-secretors on binding of meningococci to epithelial cells

Zorgani¹,

Stewart²,

Blackwell³

et al. 1994

FEMS Immunology &Amp; Medical Microbiology

View full text Add to dashboard Cite

Carriage of Neisseria meningitidis B:4:P1.15 was higher among non-secretors during a school outbreak of meningitis; non-secretors had lower levels of anti-meningococcal salivary IgM. Flow cytometry was used to assess effects of secretor and non-secretor saliva on binding of B:4:P1.15 to buccal epithelial cells: (1) to assess inhibition by IgA and IgM; and (2) to assess contributions of salivary antibodies to inhibitory activities. Greater inhibition was obtained with secretor saliva: pooled (P = 0.049); fresh (P = 0.0001). Purified IgA (P = 0.02) and IgM (P = 0.03) were equally inhibitory. After absorption of anti-meningococcal antibodies, there was still significant inhibitory activity in the pools: secretors (P = 0.018); non-secretors (P = 0.005). These results indicate that both secretory immunoglobulins and other factors contribute to protection against colonisation by meningococci and might explain the increased carriage of B:4:1.15 in this population.

show abstract

Secretory immunoglobulin A and inhibitory activity of bacterial adherence to epithelial cells in urine from patients with urinary tract infections

Cited by 31 publications

References 20 publications

Antigen-Specific Responses Accelerate Bacterial Clearance in the Bladder

Antigen-Specific Responses Accelerate Bacterial Clearance in the Bladder

Waging War against UropathogenicEscherichia coli: Winning Back the Urinary Tract

Inhibitory effect of saliva from secretors and non-secretors on binding of meningococci to epithelial cells

Contact Info

Product

Resources

About